Q1 Earnings Forecast for Inozyme Pharma Issued By Wedbush

Inozyme Pharma, Inc. (NASDAQ:INZY) – Equities researchers at Wedbush issued their Q1 2025 EPS estimates for shares of Inozyme Pharma in a research report issued on Monday, March 10th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.43) per share for the quarter. Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at ($1.01) EPS and FY2027 earnings at ($0.80) EPS.

INZY has been the subject of a number of other reports. Wells Fargo & Company cut their price objective on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Piper Sandler reduced their price target on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Inozyme Pharma in a research note on Tuesday. Raymond James lowered their price target on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Needham & Company LLC decreased their price objective on shares of Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $14.56.

Inozyme Pharma Stock Up 0.0 %

INZY stock opened at $1.00 on Thursday. The stock has a fifty day moving average of $1.44 and a 200-day moving average of $3.23. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. Inozyme Pharma has a fifty-two week low of $0.98 and a fifty-two week high of $7.80. The company has a market capitalization of $64.24 million, a price-to-earnings ratio of -0.64 and a beta of 1.32.

Institutional Trading of Inozyme Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. OneDigital Investment Advisors LLC increased its stake in shares of Inozyme Pharma by 51.5% in the third quarter. OneDigital Investment Advisors LLC now owns 20,000 shares of the company’s stock worth $105,000 after buying an additional 6,800 shares during the period. Eventide Asset Management LLC boosted its holdings in shares of Inozyme Pharma by 5.0% during the third quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock worth $21,623,000 after purchasing an additional 198,216 shares during the period. Readystate Asset Management LP bought a new stake in shares of Inozyme Pharma in the third quarter worth about $100,000. State Street Corp lifted its holdings in Inozyme Pharma by 5.0% in the 3rd quarter. State Street Corp now owns 1,050,420 shares of the company’s stock worth $5,494,000 after buying an additional 50,386 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Inozyme Pharma by 11.9% in the 3rd quarter. Wellington Management Group LLP now owns 260,719 shares of the company’s stock worth $1,364,000 after buying an additional 27,739 shares during the last quarter. Institutional investors own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.